These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 22268920)

  • 1. Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study.
    Nielsen SE; Persson F; Frandsen E; Sugaya T; Hess G; Zdunek D; Shjoedt KJ; Parving HH; Rossing P
    Diabet Med; 2012 Aug; 29(8):e184-90. PubMed ID: 22268920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function.
    van den Meiracker AH; Baggen RG; Pauli S; Lindemans A; Vulto AG; Poldermans D; Boomsma F
    J Hypertens; 2006 Nov; 24(11):2285-92. PubMed ID: 17053552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short term effect of an aldose reductase inhibitor on urinary albumin excretion rate (UAER) and glomerular filtration rate (GFR) in type 1 diabetic patients with incipient nephropathy.
    Ranganathan S; Krempf M; Feraille E; Charbonnel B
    Diabete Metab; 1993; 19(2):257-61. PubMed ID: 8339858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of spironolactone on nephron function in patients with diabetic nephropathy.
    Ustundag A; Tugrul A; Ustundag S; Sut N; Demirkan B
    Ren Fail; 2008; 30(10):982-91. PubMed ID: 19016150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term renoprotection by perindopril or nifedipine in non-hypertensive patients with Type 2 diabetes and microalbuminuria.
    Jerums G; Allen TJ; Campbell DJ; Cooper ME; Gilbert RE; Hammond JJ; O'Brien RC; Raffaele J; Tsalamandris C;
    Diabet Med; 2004 Nov; 21(11):1192-9. PubMed ID: 15498085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of enalapril and nitrendipine on exercise albuminuria in normotensive type I diabetic patients with incipient nephropathy.
    Heinemann L; Janicke I; Bender R; Berger M; Sawicki PT
    Horm Metab Res; 1996 Oct; 28(10):549-52. PubMed ID: 8934214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autoregulation of glomerular filtration rate during spironolactone treatment in hypertensive patients with type 1 diabetes: a randomized crossover trial.
    Schjoedt KJ; Christensen PK; Jorsal A; Boomsma F; Rossing P; Parving HH
    Nephrol Dial Transplant; 2009 Nov; 24(11):3343-9. PubMed ID: 19561152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy and tolerability of fosinopril in Chinese type 2 diabetic patients with moderate renal insufficiency.
    Tong PC; Ko GT; Chan WB; Ma RC; So WY; Lo MK; Lee KF; Ozaki R; Chow CC; Cockram CS; Chan JC
    Diabetes Obes Metab; 2006 May; 8(3):342-7. PubMed ID: 16634995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-term suppression of elevated growth hormone concentrations following insulin-like growth factor 1 administration in young adults with type 1 diabetes does not alter glomerular filtration or albumin excretion rates.
    Williams RM; Yuen K; White D; Mallard B; Dalton RN; Acerini CL; Dunger DB
    Clin Endocrinol (Oxf); 2006 Oct; 65(4):439-45. PubMed ID: 16984235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beneficial impact of spironolactone in diabetic nephropathy.
    Schjoedt KJ; Rossing K; Juhl TR; Boomsma F; Rossing P; Tarnow L; Parving HH
    Kidney Int; 2005 Dec; 68(6):2829-36. PubMed ID: 16316360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spironolactone further reduces urinary albumin excretion and plasma B-type natriuretic peptide levels in hypertensive type II diabetes treated with angiotensin-converting enzyme inhibitor.
    Ogawa S; Takeuchi K; Mori T; Nako K; Ito S
    Clin Exp Pharmacol Physiol; 2006; 33(5-6):477-9. PubMed ID: 16700881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vitamin D analogue therapy, cardiovascular risk and kidney function in people with Type 1 diabetes mellitus and diabetic nephropathy: a randomized trial.
    Joergensen C; Tarnow L; Goetze JP; Rossing P
    Diabet Med; 2015 Mar; 32(3):374-81. PubMed ID: 25307511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive Type 2 diabetic patients with microalbuminuria: DIAL study (diabete, ipertensione, albuminuria, lercanidipina).
    Dalla Vestra M; Pozza G; Mosca A; Grazioli V; Lapolla A; Fioretto P; Crepaldi G
    Diabetes Nutr Metab; 2004 Oct; 17(5):259-66. PubMed ID: 16295047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study.
    Rossing K; Schjoedt KJ; Smidt UM; Boomsma F; Parving HH
    Diabetes Care; 2005 Sep; 28(9):2106-12. PubMed ID: 16123474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
    Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
    Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects on heart rate variability of metoprolol supplementary to ongoing ACE-inhibitor treatment in Type I diabetic patients with abnormal albuminuria.
    Ebbehøj E; Poulsen PL; Hansen KW; Knudsen ST; Mølgaard H; Mogensen CE
    Diabetologia; 2002 Jul; 45(7):965-75. PubMed ID: 12136395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of addition of silymarin to renin-angiotensin system inhibitors on proteinuria in type 2 diabetic patients with overt nephropathy: a randomized, double-blind, placebo-controlled trial.
    Fallahzadeh MK; Dormanesh B; Sagheb MM; Roozbeh J; Vessal G; Pakfetrat M; Daneshbod Y; Kamali-Sarvestani E; Lankarani KB
    Am J Kidney Dis; 2012 Dec; 60(6):896-903. PubMed ID: 22770926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal protection and angiotensin converting enzyme inhibition in microalbuminuric type I and type II diabetic patients.
    Cooper ME
    J Hypertens Suppl; 1996 Dec; 14(6):S11-4. PubMed ID: 9023709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Kidney Injury Molecule 1 (KIM1) in patients with diabetic nephropathy: a cross-sectional study and the effects of lisinopril.
    Nielsen SE; Schjoedt KJ; Astrup AS; Tarnow L; Lajer M; Hansen PR; Parving HH; Rossing P
    Diabet Med; 2010 Oct; 27(10):1144-50. PubMed ID: 20854382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tubular and glomerular injury in diabetes and the impact of ACE inhibition.
    Nielsen SE; Sugaya T; Tarnow L; Lajer M; Schjoedt KJ; Astrup AS; Baba T; Parving HH; Rossing P
    Diabetes Care; 2009 Sep; 32(9):1684-8. PubMed ID: 19502542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.